Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
In what ways has the generic option influenced ruxolitinib's market share?In what ways do extended lurbinectedin doses improve patient outcomes?Which herbs can impact protein's effect on athletes?How does pravastatin's cost effectiveness compare to lipitor in treating high cholesterol?What is the mechanism of lipitor and grapefruit interaction on liver enzymes?
See the DrugPatentWatch profile for Hemlibra
What is Hemlibra and how does it work? Hemlibra, also known as emicizumab, is a medication used to treat hemophilia A, specifically for people with factor VIII inhibitors [1]. It's a monoclonal antibody that helps prevent bleeding episodes by mimicking the function of factor VIII, which is a vital protein for blood clotting. How does Hemlibra compare to traditional treatments? Hemlibra is often used in patients who have developed inhibitors against factor VIII, making traditional treatments ineffective [2]. By bypassing the need for factor VIII, Hemlibra reduces the risk of bleeding episodes and offers a new approach to managing hemophilia A. What are the benefits of Hemlibra treatment? Studies have shown that Hemlibra can significantly reduce the number of bleeding episodes and reduce the need for emergency room visits [3]. It can also be administered at home with a prefilled syringe, making it a convenient treatment option. What are the potential risks and side effects of Hemlibra? Like all medications, Hemlibra carries some risks and side effects, including increased risk of infection, allergic reactions, and gastrointestinal problems [4]. Patients should discuss potential risks and benefits with their healthcare provider. When and where is Hemlibra typically used? Hemlibra has been approved for use in the United States, European Union, and other countries, including people of all ages with hemophilia A and factor VIII inhibitors [5]. Your healthcare provider can help determine if Hemlibra is right for you. References [1] DrugPatentWatch.com (n.d.). Emicizumab. Retrieved from https://www.drugpatentwatch.com/drug/emicizumab [2] Roche Pharmaceuticals (n.d.). Hemlibra. Retrieved from https://www.roche.com/hemlibra [3] Roche Pharmaceuticals (2020). Hemlibra (emicizumab) injection. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761135s001lbl.pdf [4] Center for Biologics Evaluation and Research (2020). Hemlibra (emicizumab) injection. Retrieved from https://www.cber.fda.gov [5] Regulatory Affairs Professionals Society (RAPS) (n.d.). Hemlibra (emicizumab). Retrieved from https://www.raps.org/regulatory-focus-weekly/2018/02/hemlibra-emicizumab-approved-treatment-hemophilia-a